Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008292564> ?p ?o ?g. }
- W3008292564 endingPage "870" @default.
- W3008292564 startingPage "856" @default.
- W3008292564 abstract "Abstract Contemporary data indicate that patients with signs and symptoms of ischaemia and non-obstructive coronary artery disease (INOCA) often have coronary microvascular dysfunction (CMD) with elevated risk for adverse outcomes. Coronary endothelial (constriction with acetylcholine) and/or microvascular (limited coronary flow reserve with adenosine) dysfunction are well-documented, and extensive non-obstructive atherosclerosis is often present. Despite these data, patients with INOCA currently remain under-treated, in part, because existing management guidelines do not address this large, mostly female population due to the absence of evidence-based data. Relatively small sample-sized, short-term pilot studies of symptomatic mostly women, with INOCA, using intense medical therapies targeting endothelial, microvascular, and/or atherosclerosis mechanisms suggest symptom, ischaemia, and coronary vascular functional improvement, however, randomized, controlled outcome trials testing treatment strategies have not been completed. We review evidence regarding CMD pharmacotherapy. Potent statins in combination with angiotensin-converting enzyme inhibitor (ACE-I) or receptor blockers if intolerant, at maximally tolerated doses appear to improve angina, stress testing, myocardial perfusion, coronary endothelial function, and microvascular function. The Coronary Microvascular Angina trial supports invasive diagnostic testing with stratified therapy as an approach to improve symptoms and quality of life. The WARRIOR trial is testing intense medical therapy of high-intensity statin, maximally tolerated ACE-I plus aspirin on longer-term outcomes to provide evidence for guidelines. Novel treatments and those under development appear promising as the basis for future trial planning." @default.
- W3008292564 created "2020-03-06" @default.
- W3008292564 creator A5012657143 @default.
- W3008292564 creator A5062232887 @default.
- W3008292564 creator A5083852582 @default.
- W3008292564 creator A5084059173 @default.
- W3008292564 date "2020-02-22" @default.
- W3008292564 modified "2023-10-15" @default.
- W3008292564 title "Treatment of coronary microvascular dysfunction" @default.
- W3008292564 cites W108421368 @default.
- W3008292564 cites W137885719 @default.
- W3008292564 cites W1481279260 @default.
- W3008292564 cites W1538751400 @default.
- W3008292564 cites W1811184201 @default.
- W3008292564 cites W1849851713 @default.
- W3008292564 cites W1868111277 @default.
- W3008292564 cites W1943446280 @default.
- W3008292564 cites W1966645232 @default.
- W3008292564 cites W1967146205 @default.
- W3008292564 cites W1970402870 @default.
- W3008292564 cites W1972909012 @default.
- W3008292564 cites W1978584044 @default.
- W3008292564 cites W1982642084 @default.
- W3008292564 cites W1982695532 @default.
- W3008292564 cites W1987468165 @default.
- W3008292564 cites W1991979617 @default.
- W3008292564 cites W1992583442 @default.
- W3008292564 cites W1996521009 @default.
- W3008292564 cites W2000436057 @default.
- W3008292564 cites W2001966526 @default.
- W3008292564 cites W2002329208 @default.
- W3008292564 cites W2004889205 @default.
- W3008292564 cites W2006654512 @default.
- W3008292564 cites W2007238256 @default.
- W3008292564 cites W2012296672 @default.
- W3008292564 cites W2017521083 @default.
- W3008292564 cites W2019262320 @default.
- W3008292564 cites W2021137215 @default.
- W3008292564 cites W2021803963 @default.
- W3008292564 cites W2024990134 @default.
- W3008292564 cites W2033611117 @default.
- W3008292564 cites W2034813965 @default.
- W3008292564 cites W2036469650 @default.
- W3008292564 cites W2037398235 @default.
- W3008292564 cites W2039200432 @default.
- W3008292564 cites W2041469109 @default.
- W3008292564 cites W2041745893 @default.
- W3008292564 cites W2042104057 @default.
- W3008292564 cites W2042227371 @default.
- W3008292564 cites W2044013576 @default.
- W3008292564 cites W2044474620 @default.
- W3008292564 cites W2045389499 @default.
- W3008292564 cites W2047665781 @default.
- W3008292564 cites W2047789242 @default.
- W3008292564 cites W2048320533 @default.
- W3008292564 cites W2053313238 @default.
- W3008292564 cites W2053351192 @default.
- W3008292564 cites W2057139885 @default.
- W3008292564 cites W2060231842 @default.
- W3008292564 cites W2060618473 @default.
- W3008292564 cites W2061031633 @default.
- W3008292564 cites W2062676382 @default.
- W3008292564 cites W2068717153 @default.
- W3008292564 cites W2076117228 @default.
- W3008292564 cites W2076834039 @default.
- W3008292564 cites W2084583665 @default.
- W3008292564 cites W2084879646 @default.
- W3008292564 cites W2085677106 @default.
- W3008292564 cites W2086832765 @default.
- W3008292564 cites W2087023213 @default.
- W3008292564 cites W2087601873 @default.
- W3008292564 cites W2095233049 @default.
- W3008292564 cites W2095241420 @default.
- W3008292564 cites W2097149179 @default.
- W3008292564 cites W2101719835 @default.
- W3008292564 cites W2108923694 @default.
- W3008292564 cites W2110123637 @default.
- W3008292564 cites W2114101393 @default.
- W3008292564 cites W2115841204 @default.
- W3008292564 cites W2116615883 @default.
- W3008292564 cites W2117342023 @default.
- W3008292564 cites W2124659021 @default.
- W3008292564 cites W2129518889 @default.
- W3008292564 cites W2130732338 @default.
- W3008292564 cites W2136924707 @default.
- W3008292564 cites W2141681173 @default.
- W3008292564 cites W2142721799 @default.
- W3008292564 cites W2142935346 @default.
- W3008292564 cites W2144207672 @default.
- W3008292564 cites W2148558291 @default.
- W3008292564 cites W2154945560 @default.
- W3008292564 cites W2155564732 @default.
- W3008292564 cites W2158272601 @default.
- W3008292564 cites W2160272600 @default.
- W3008292564 cites W2162910459 @default.
- W3008292564 cites W2167122102 @default.
- W3008292564 cites W2169590333 @default.
- W3008292564 cites W2196103352 @default.